The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Poster
Other/Multi
ASCO 2025 | May 30-June 3,2025
Other/Multi
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors
Sandra P. D'Angelo
View presentation
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Other/Multi
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Zenta Tsuchihashi
View presentation
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
Other/Multi
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Toshihiko Doi
View presentation
Oral
Pipeline Compounds
ESMO 2025 | October 17-21, 2025
Other/Multi
DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate, in patients with advanced/metastatic solid tumors: Initial results from a first-in-human study
Manish R. Patel
View presentation
Poster
Valemetostat
ASCPT 2025 | May 28-31, 2025
Other/Multi
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin (CYP3A and P-gp substrates): A phase 1 drug–drug interaction study in patients with refractory or relapsed non-hodgkin lymphoma
Masaya Tachibana
View presentation
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
Other/Multi
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Izuma Nakayama
View presentation
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
Other/Multi
KEYMAKER-U06 Substudy O6E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma
Ken Kato
View presentation
Poster
T-DXd
AMCP Nexus 2025 | October 27-30, 2025
Other/Multi
Patient characteristics, treatment patterns, and real-world outcomes among patients in the US with human epidermal growth factor receptor 2-expressing solid tumors
Anuj Shah
View presentation
Oral
Dato-DXd, T-DXd, Valemetostat
AACR 2025 | April 25-29, 2025
Other/Multi
Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors
Daisuke Honma
View presentation
Poster
R-DXd
ASCO 2025 | May 30-June 3,2025
Other/Multi
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic solid tumors
Laurence Albiges
View presentation
Pages: 1  2  
Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24